Sofinnova Investments’s XBiotech XBIT Stock Holding History

Sofinnova Investments’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-240,995	Closed	-$4.5M	–	70
2019 Q4	$4.5M	Sell	240,995 -117,668	-33%	-$1.52M	0.32%	46
2019 Q3	$3.75M	Buy	358,663 +26,852	+8%	+$219K	0.34%	46
2019 Q2	$2.52M	Buy	331,811 +70,420	+27%	+$612K	0.23%	50
2019 Q1	$2.88M	Buy	+261,391	New	+$2.12M	0.28%	51

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Sofinnova Investments's XBIT Position: Q1 2020 in Review

Sofinnova Investments sold out of XBiotech (XBIT) in Q1 2020, closing a stake of 240,995 shares — an estimated $4.5M sold.

Sofinnova Investments first reported a position in XBIT in Q1 2019 and held it in 4 quarters. The position peaked at $4.5M in Q4 2019. 60 funds tracked by Wall St. Rank hold XBIT as of Q1 2020.

Sofinnova Investments reported no remaining XBiotech position as of Q1 2020 after selling out during the quarter.
Sofinnova Investments sold 240,995 XBiotech shares in Q1 2020, an estimated $4.5M.
Sofinnova Investments first reported a position in XBiotech in Q1 2019 and held it in 4 quarters.
Sofinnova Investments's XBiotech position peaked at $4.5M in Q4 2019.
60 funds tracked by Wall St. Rank held XBiotech as of Q1 2020.

Based on Sofinnova Investments's 13F filing for Q1 2020, filed 13 May 2020.